Enhanced AKT activation has been documented in CLL patients who progress on noncovalent BTK inhibitors such as pirtobrutinib, indicating a compensatory mechanism that sustains malignant cell viability in the absence of effective BTK signaling [104]. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.